We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+9.29%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.5B
AUM Growth
-$325M
(-11%)
Cap. Flow
-$480M
Cap. Flow
% of AUM
-19.19%
Top 10 Holdings %
Top 10 Hldgs %
43.13%
Holding
114
New
31
Increased
17
Reduced
20
Closed
42
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$104M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$96.5M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$96.1M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$86.3M |
| 5 |
Natera
NTRA
|
+$80.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$115M |
| 2 |
Incyte
INCY
|
+$95.4M |
| 3 |
Agios Pharmaceuticals
AGIO
|
+$79.2M |
| 4 |
AbbVie
ABBV
|
+$78.9M |
| 5 |
IQVIA
IQV
|
+$77.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.3% |
| 2 | Consumer Discretionary | 4.43% |
| 3 | Real Estate | 2.56% |
| 4 | Financials | 1.86% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$18.4B
| $123M | 4.91% |
787,260
+4,790
| +0.6% | +$776K |
|
2
Biogen
BIIB
$30.7B
| $117M | 4.7% |
339,300
+258,790
| +321% | +$78.4M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $116M | 4.62% |
1,235,048
-490,602
| -28% | -$45.1M |
|
4
Petco
WOOF
$794M
| $111M | 4.43% |
4,944,450
+1,856,450
| +60% | +$43.4M |
|
|
5
Regeneron Pharmaceuticals
REGN
$76B
| $106M | 4.25% |
+190,380
| New | +$96.5M |
|
6
Humana
HUM
$44B
| $106M | 4.23% |
239,030
-12,360
| -5% | -$5.4M |
|
|
7
CVS Health
CVS
$134B
| $106M | 4.23% |
+1,267,330
| New | +$104M |
|
8
Danaher
DHR
$138B
| $103M | 4.13% |
434,190
-170,046
| -28% | -$37.7M |
|
|
9
Bristol-Myers Squibb
BMY
$132B
| $98.5M | 3.94% |
+1,474,370
| New | +$96.1M |
|
|
10
Thermo Fisher Scientific
TMO
$214B
| $92.3M | 3.69% |
+182,970
| New | +$86.3M |
|
|
11
Natera
NTRA
$38.6B
| $89.7M | 3.58% |
+789,658
| New | +$80.8M |
|
12
Encompass Health
EHC
$11B
| $82.3M | 3.29% |
1,326,532
+62,850
| +5% | +$4.19M |
|
13
Medtronic
MDT
$110B
| $74.6M | 2.98% |
600,720
-195,390
| -25% | -$24.5M |
|
14
Align Technology
ALGN
$12.4B
| $72.6M | 2.9% |
118,780
+47,320
| +66% | +$28M |
|
15
Stryker
SYK
$133B
| $71M | 2.84% |
+273,190
| New | +$69.9M |
|
|
NVRO
16
DELISTED
NEVRO CORP.
NVRO
| $62.4M | 2.49% |
+376,330
| New | +$58.7M |
|
17
Maravai LifeSciences
MRVI
$996M
| $52.4M | 2.09% |
1,255,597
-1,157,115
| -48% | -$44.8M |
|
18
Boston Scientific
BSX
$68.4B
| $51.8M | 2.07% |
1,210,570
+35,750
| +3% | +$1.5M |
|
19
BioCryst Pharmaceuticals
BCRX
$2.35B
| $51.4M | 2.05% |
3,248,100
-1,638,340
| -34% | -$22.3M |
|
20
Envista
NVST
$4.52B
| $50.4M | 2.01% |
1,165,860
-269,510
| -19% | -$11.7M |
|
21
Universal Health Services
UHS
$9.88B
| $47.7M | 1.91% |
+325,577
| New | +$49.2M |
|
22
Zoetis
ZTS
$31.9B
| $42.7M | 1.71% |
229,170
-192,690
| -46% | -$33.5M |
|
23
Veeva Systems
VEEV
$32.7B
| $42.3M | 1.69% |
136,080
+50,180
| +58% | +$14M |
|
24
Amgen
AMGN
$209B
| $38.6M | 1.54% |
+158,280
| New | +$38.9M |
|
25
Neurocrine Biosciences
NBIX
$18.7B
| $38M | 1.52% |
+389,980
| New | +$37.4M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2021 Portfolio in Review
As of Q2 2021, HealthCor Management held 114 positions worth $2.5B, down 11% from $2.83B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
HealthCor Management withdrew a net $480M in Q2 2021, closing 42 positions and reducing 20 holdings. Its most notable exit was Incyte, an estimated $95.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier, followed by Consumer Discretionary and Real Estate.
Against the trend, HealthCor Management opened a new position in CVS Health worth $106M.
- HealthCor Management's largest Q2 2021 buy was CVS Health: 1,267,330 shares worth $106M.
- HealthCor Management added most to Biogen in Q2 2021, an estimated $78.4M increase.
- HealthCor Management's biggest Q2 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $115M.
- HealthCor Management fully exited Incyte in Q2 2021, selling an estimated $95.4M.
- HealthCor Management's ten largest holdings make up 43% of its $2.5B portfolio in Q2 2021.
- HealthCor Management opened 31 new positions and closed 42 in Q2 2021.
- HealthCor Management's portfolio value fell 11% quarter-over-quarter to $2.5B.
Based on HealthCor Management's 13F filing for Q2 2021, filed 16 Aug 2021.